PER 2.47% 8.3¢ percheron therapeutics limited

@murrayrt Number of reasons One was the partial hold on 1102 for...

  1. 4,073 Posts.
    lightbulb Created with Sketch. 1817
    @murrayrt

    Number of reasons
    One was the partial hold on 1102 for MS

    Plus the company made it known they would no longer chase the RRMS as the space was overcrowded

    So the idea was to do a crossover trial into SPMS which is another unmet field

    But to do this because we have no data on SPMS we had to carry a number of RRMS patients along with a number of SPMS to convert the trial over and onto SPMS

    Which i am also tipping there could well be something written in the DMD trial along those lines so that we can incorporate the ambulant boys into our DMD programme

    Because the advice we are going to get on Monday is basically the guidance and uses market

    Back to the RRMS so the trial was going to be to expensive and we redirected into DMD which obviously was the correct move

    But if funds eventuate from a deal then this opens up the SPMS route for continuation although a little work to do with the FDA before it could advance

    We have the goods i have always believed this

    It's not the pipeline I'm worried about its the figures like i said the next move funding wise will determine not when but how fast we join the elite in pharma land

    Fingers crossed

    See how we go
    Last edited by samfiodiving: 15/10/21
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.3¢
Change
0.002(2.47%)
Mkt cap ! $74.82M
Open High Low Value Volume
9.0¢ 9.0¢ 8.2¢ $9.57K 112.6K

Buyers (Bids)

No. Vol. Price($)
2 124862 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 11000 1
View Market Depth
Last trade - 15.56pm 28/03/2024 (20 minute delay) ?
Last
8.2¢
  Change
0.002 ( 0.86 %)
Open High Low Volume
8.2¢ 8.3¢ 8.2¢ 31700
Last updated 15.55pm 28/03/2024 ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.